Give IPR the Green Light

IPR (Inter Partes Review) works. It expedites the pathway for generic and biosimilar medicines to come to market and it rewards true innovation. It's time for Congress to take action to enhance the PTO's IPR authority.

Read Blog
New Analysis of the BLOCKING Act

New report from Matrix Global Advisors finds the delay of just one generic medicine will increase prescription drug costs for patients by $1.7 billion.

View Press Release
The CREATES Act Passed!

The CREATES Act passed! Patients will now score greater savings and increased access to generic and biosimilar medicines.
Watch Video
A Victory for America's Patients

The revised USMCA creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries. #FixedUSMCA

Read Press Release
Access for All

Access! 2020 is coming to Washington, D.C. May 11-13. Meet the leaders and decision-makers who are determining the future of generics and biosimilars.

Learn More
Generic Medicines Are Saving Your State Billions

AAM's 2019 interactive state savings map is now live! Explore the clickable map to find out how much generic drugs save the U.S.—and each state—in health care costs.

View Map
#DoesntAddUp

If generic prescription drug prices are falling each year, why are consumer costs for prescription drugs rising?

Take Action
The Case for Competition

Now available: AAM's full 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report

Read Full Report

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Jan 16, 2020 | Rachel Schwartz

AAM Statement on Senate Passage of USMCA Agreement

Jan 9, 2020 | Karin Hessler

Competition Matters. That’s Why We Need to Further Improve IPR.

Jan 8, 2020 | Rachel Schwartz

AAM Statement on "The Unintended Economics of the BLOCKING Act" Report

Jan 7, 2020 | Rachel Schwartz

Katherine Michelle Raab Joins AAM as Vice President, Federal Government Affairs

Video

Dec 20, 2019 | Erica Klinger

The CREATES Act Passed! — #PassedCREATES

Dec 19, 2019 | Rachel Schwartz

USMCA Sets a New Standard for Lowering Drug Prices and Expanding Access to Medicines